5 Best Immunotherapy Stocks To Buy Now

1. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 88

Johnson & Johnson (NYSE:JNJ) is a global healthcare company engaged in research, development, manufacturing, and distribution of healthcare products across the world. In its Pharmaceutical segment, the company offers a wide range of products addressing various medical conditions, including prostate cancer, hematologic malignancies, lung cancer, bladder cancer, autoimmune diseases, infectious diseases, mental health disorders, as well as treatments for thrombosis, diabetes, macular degeneration, and pulmonary arterial hypertension. On September 6, Johnson & Johnson’s Janssen division reported a significant milestone with its bispecific antibody Rybrevant, which successfully met the dual primary objective of extending progression-free survival in a Phase 3 clinical trial involving lung cancer patients with specific genetic mutations.

The pharmaceutical division of Johnson & Johnson (NYSE:JNJ) has an impressive track record of maintaining dividend growth for over 62 years. As of October 26, the company offers a quarterly dividend of $1.19 per share, providing a dividend yield of 3.27%.

On October 17, Johnson & Johnson (NYSE:JNJ) announced better-than-expected adjusted earnings and revenue, leading to an increase in its full-year guidance. The strong performance was driven by robust sales in both its pharmaceutical and medical devices divisions. The company also disclosed a net income of $4.31 billion, which equates to $1.69 per share, consistent with the net income of $4.31 billion, or $1.62 per share, reported for the corresponding period in the previous year.

In the second quarter of 2023, the number of hedge funds with holdings in Johnson & Johnson (NYSE:JNJ), as tracked by Insider Monkey, increased to 88, up from 86 in the previous quarter. These hedge funds collectively invested a total value of over $4.1 billion. The largest hedge fund investor in Johnson & Johnson is Bridgewater Associates, managed by Ray Dalio, with a significant stake valued at approximately $526.58 million.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out 12 Best Artificial Intelligence (AI) Stocks To Buy According to Hedge Funds and Top 25 Digital Countries in the World.